From Peptides to Pills: The Oral Obesity Drug Revolution
- Highlight formulation challenges behind bioavailability and titration
- Predict market shifts if oral efficacy rivals injectables
- Discussing transition pipelines to small molecules to understand benefits and disadvantages of changing to different therapies
- Ensuring future portfolios against peptide production bottlenecks to reduce costs and unnecessary pollutants